MiniMed Group Inc 2026年季度报告

FORM 10-Q QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934For the quarterly period ended January23, 2026 Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.For the transition period from __________ to __________ Commission File Number 001-43183 MiniMed Group, Inc.(Exact name of registrant as specified in its charter) 18000 Devonshire St.Northridge, CA 91325(Address of principal executive offices) (Zip Code)(763) 514-4000(Registrant’s telephone number, including area code) Securities registered pursuant to Section 12(b) of the Act: Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities ExchangeAct of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports) and (2) hasbeen subject to such filing requirements for the past 90 days. Yes☐No☒ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant toRule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant wasrequired to submit and post such files). Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reportingcompany, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reportingcompany,” and "emerging growth company" in Rule 12b-2 of the Exchange Act. Large accelerated filer☐Accelerated filer☐Emerging growth companyNon-accelerated filer☒Smaller Reporting Company☐ Ifanemerginggrowthcompany,indicatebycheckmarkiftheregistranthaselectednottousetheextendedtransition period forcomplying with any new or revised financial accounting standards provided pursuant to Section1(a)oftheExchangeAct.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes☐No☒ As of April11, 2026, 280,819,988 shares of the registrant were outstanding. TABLE OF CONTENTS MINIMED GROUP, INC.CONDENSED COMBINED BALANCE SHEETS MINIMED GROUP, INC.CONDENSED COMBINED STATEMENTS OF CASH FLOWS(Unaudited) MINIMED GROUP, INC.NOTES TO CONDENSED COMBINED FINANCIAL STATEMENTS(UNAUDITED) Note 1. Description of the Business and Basis of Presentation MiniMed Group, Inc. (“MiniMed” or the “Company”) is a medical technology company focused on the development, manufacture,and commercialization of insulin pumps, continuous glucose monitoring (“CGM”) systems, related consumables, smart pens, and digitalhealth solutions for the management of Type 1 and Type 2 diabetes. Basis of Presentation Prior to March 6, 2026, the Company operated as the diabetes business of Medtronic plc (“Medtronic” or the “Parent”) and did notexist as a separate, stand‑alone legal entity. The accompanying unaudited condensed combined financial statements present the historicalfinancial position, results of operations, and cash flows of the diabetes business as historically managed within Medtronic (the “DiabetesBusiness” or the “Company”), prepared on a carve‑out basis in accordance with accounting principles generally accepted in the UnitedStates (“U.S. GAAP”). The condensed combined financial statements have been prepared in U.S. dollars and should be read in conjunction with theCompany’s audited combined financial statements and related notes for the fiscal year ended April 25, 2025, contained in the Company’sfinal prospectus filed on March 6, 2026 with the Securities and Exchange Commission (the “SEC”) pursuant to Rule 424(b)(4) under theSecurities Act of 1933, as amended, relating to the Registration Statement on Form S-1 (the “IPO Prospectus”). The accounting policiesapplied are consistent with those used by Medtronic. In the opinion of management, these condensed combined financial statements reflectall adjustments necessary for a fair statement of the Company’s financial position, results of operations, and cash flows for the periodspresented. The condensed combined financial statements are unaudited and, due to rounding, certain totals may not sum precisely. All revenues, costs, assets, and liabilities that are either legally attributable to or directly associated with the Company’s businessactivities are included in the condensed combined financial statements herein. Also, the Company has historically functioned together withother businesses controlled by Medtronic. Accordingly, the Company relied on Medtronic's corporate and other support functions for itsbusiness and certain corporate and shared expenses have been allocated, including, but not limited to, finance and accounting, legal,information technology, human resources, facilities, warehousing, distribution, logistics, marketing, insurance, employee benefits andincentives, restructuring and a